정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1997 | Recruiting | Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (Long-COVID) | Cognitive Symptom | Drug: Niagen | Phase 4 | Massachusetts General Hospital | OTHER | 100 | All | 18 Years ~ 65 Years | Clinical Translational Research Unit, Boston, Massachusetts, United States |
| 1996 | Recruiting | Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19 | Type 2 Diabetes | Drug: Pioglitazone 30 mg Other: standard of care |
Phase 4 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | OTHER | 76 | All | 18 Years | Hospital Ramon y Cajal, Madrid, Spain |
| 1995 | Active, not recruiting | Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 | Covid19 | Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Biological: Placebo |
Phase 3 | NPO Petrovax, CanSino Biologics Inc. | INDUSTRY | 500 | All | 18 Years ~ 85 Years | Municipal budgetary institution "Central City Hospital No. 7", Ekaterinburg, Russian Federation Federal budgetary institution of science "Central Research Institute of Epidemiology" of the Federal Service for Surveillance on Consumer Rights Protectionand Human Welfare, Moscow, Russian Federation State Budgetary Institution of Healthcare of the City of Moscow "City Polyclinic No. 2of the Department of Healthcare of the City of Moscow", Moscow, Russian Federation Federal State Autonomous Educational Institution of Higher Education "First MoscowState Medical University named after I.M. Sechenov "of the Ministry of Health of the Russian Federation, Moscow, Russian Federation Limited Liability Company "Research Center Eco-safety", Saint Petersburg, Russian Federation Federal State Budgetary Institution "Research Institute of Influenza named after A.A.Smorodintsev "of the Ministry of Health of the Russian Federation, Saint Petersburg, Russian Federation Private health care institution "Clinical hospital 'Russian Railways - Medicine' of the city of Yaroslavl", Yaroslavl, Russian Federation |
| 1994 | Completed | Clinical Trial of Sarilumab in Adults With COVID-19 | SARS | Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] Drug: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA] Drug: Best available treatment |
Phase 2 | Maimonides Biomedical Research Institute of Cordoba, Consejeria de Salud y Familias - Junta de Andalucia, Red Andaluza de Ensayos Clinicos en Enfermedades Infecciosas (Red ANCRAID) | OTHER | 120 | All | 18 Years ~ 75 Years | Hospital Universitario Reina Sofia, Cordoba, Spain |
| 1993 | Not yet recruiting | Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19) | COVID-19 | Biological: SARS-CoV-2 Vaccine (Vero Cells), Inactivated Biological: Placebo |
Phase 1 | Shenzhen Kangtai Biological Products Co., LTD, Beijing Minhai Biotechnology Co., Ltd, Hunan Province Centers for Disease Control and Prevention | INDUSTRY | 84 | All | 3 Years ~ 17 Years | Hunan Provincial Center for Diseases Control and Prevention, Changsha, Hunan, China |
| 1992 | Recruiting | Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil | Healthy | Biological: NDV-HXP-S 1μg (Stage A) Biological: NDV-HXP-S 3μg (Stage A) Biological: NDV-HXP-S 10μg (Stage A) Biological: NDV-HXP-S parental vaccine in 3 consecutive lots (Group B1a) Biological: Active vaccine control (Group B1a) Biological: NDV-HXP-S parental vaccine (Group B1b) Biological: Active vaccine control (Group B1b) Biological: NDV-HXP-S parental vaccine (Group B1c) Biological: Active vaccine control (Group B1c) Other: Placebo (Stage A) Biological: NDV-HXP-S parental vaccine simple dose (Group B1d) Biological: Active vaccine control (Group B1d) Biological: NDV-HXP-S parental vaccine simple dose (Group B1d) - 60 years old or more Biological: Active vaccine control simple dose (Group B1d) Biological: NDV-HXP-S P.1 vaccine (Group B1e) Biological: NDV-HXP-S B.1351 vaccine (Group B1e) Biological: NDV-HXP-S vaccine based in variant / 3 consecutive lots (Group C1a) Biological: NDV-HXP-S vaccine based in variant (Group C1b) Biological: NDV-HXP-S vaccine based in variant (Group C1c) Biological: NDV-HXP-S vaccine based in variant (Group C1c) - 60 years old or more Biological: NDV-HXP-S P.1 vaccine (Group B2a) Biological: NDV-HXP-S P.1.351 vaccine (Group B2a) Biological: NDV-HXP-S vaccine based in variant / 3 consecutive lots (Group C2a) Biological: Active vaccine control (Group C2a) Biological: NDV-HXP-S vaccine based in variant (Group C2b) Biological: Active vaccine control (Group C2b) Biological: NDV-HXP-S vaccine based in variant (Group C2c) Biological: Active vaccine control (Group C2c) Biological: NDV-HXP-S parental vaccine simple dose (Group C2d) Biological: Active vaccine control simple dose (Group C2d) Biological: NDV-HXP-S parental vaccine simple dose (Group C2d) - 60 years old or more Biological: Active vaccine control simple dose (Group C2d) - 60 years old or more |
Phase 2 | Butantan Institute | OTHER_GOV | 5394 | All | 18 Years | Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil |
| 1991 | Not yet recruiting | Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela | Covid19 | Biological: Gam-COVID-Vac Biological: Placebo |
Phase 3 | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation, Ministerio del Poder Popular para la Salud de la Republica Bolivariana de Venezuela | OTHER | 2000 | All | 18 Years |
